Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DROXIDOPA Cause Chronic obstructive pulmonary disease? 21 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 21 reports of Chronic obstructive pulmonary disease have been filed in association with DROXIDOPA (Droxidopa). This represents 0.1% of all adverse event reports for DROXIDOPA.

21
Reports of Chronic obstructive pulmonary disease with DROXIDOPA
0.1%
of all DROXIDOPA reports
7
Deaths
8
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From DROXIDOPA?

Of the 21 reports, 7 (33.3%) resulted in death, 8 (38.1%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DROXIDOPA. However, 21 reports have been filed with the FAERS database.

What Other Side Effects Does DROXIDOPA Cause?

Dizziness (2,823) Death (1,985) Blood pressure increased (1,862) Drug ineffective (1,602) Headache (1,555) Fall (1,351) Hypotension (1,180) Fatigue (1,142) Hypertension (1,133) Nausea (1,032)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which DROXIDOPA Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

DROXIDOPA vs DULAGLUTIDE DROXIDOPA vs DULERA DROXIDOPA vs DULOXETINE DROXIDOPA vs DUPILUMAB DROXIDOPA vs DURAGESIC

Related Pages

DROXIDOPA Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease DROXIDOPA Demographics